CCR2 and chronic kidney disease: AT1R and CCR2 were reported to functionally interact, and combined treatment with the CCR2 inhibitor DMX-200 (30 mg/kg/day) and irbesartan, another AT1R antagonist, synergistically decreased β-arrestin recruitment and inflammatory cascades in chronic kidney disease [27].